SG11201702598XA - Dosage and administration of non-fucosylated anti-cd40 antibodies - Google Patents

Dosage and administration of non-fucosylated anti-cd40 antibodies

Info

Publication number
SG11201702598XA
SG11201702598XA SG11201702598XA SG11201702598XA SG11201702598XA SG 11201702598X A SG11201702598X A SG 11201702598XA SG 11201702598X A SG11201702598X A SG 11201702598XA SG 11201702598X A SG11201702598X A SG 11201702598XA SG 11201702598X A SG11201702598X A SG 11201702598XA
Authority
SG
Singapore
Prior art keywords
antibodies
dosage
administration
fucosylated anti
fucosylated
Prior art date
Application number
SG11201702598XA
Other languages
English (en)
Inventor
Shyra Gardai
Che-Leung Law
Stanford Peng
Jing Yang
Haley Neff-Laford
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55858352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201702598X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of SG11201702598XA publication Critical patent/SG11201702598XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0009—Making of catheters or other medical or surgical tubes
    • A61M25/0012—Making of catheters or other medical or surgical tubes with embedded structures, e.g. coils, braids, meshes, strands or radiopaque coils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/002—Packages specially adapted therefor ; catheter kit packages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0068—Static characteristics of the catheter tip, e.g. shape, atraumatic tip, curved tip or tip structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11201702598XA 2014-10-29 2015-10-29 Dosage and administration of non-fucosylated anti-cd40 antibodies SG11201702598XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462072031P 2014-10-29 2014-10-29
US201562134955P 2015-03-18 2015-03-18
PCT/US2015/058108 WO2016069919A1 (en) 2014-10-29 2015-10-29 Dosage and administration of non-fucosylated anti-cd40 antibodies

Publications (1)

Publication Number Publication Date
SG11201702598XA true SG11201702598XA (en) 2017-05-30

Family

ID=55858352

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201702598XA SG11201702598XA (en) 2014-10-29 2015-10-29 Dosage and administration of non-fucosylated anti-cd40 antibodies
SG10201913099YA SG10201913099YA (en) 2014-10-29 2015-10-29 Dosage and administration of non-fucosylated anti-cd40 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913099YA SG10201913099YA (en) 2014-10-29 2015-10-29 Dosage and administration of non-fucosylated anti-cd40 antibodies

Country Status (22)

Country Link
US (8) US11213584B2 (ja)
EP (2) EP3831847A1 (ja)
JP (5) JP6691113B2 (ja)
KR (2) KR20240073140A (ja)
CN (2) CN114522228A (ja)
AU (2) AU2015339128C1 (ja)
BR (1) BR112017008959A2 (ja)
CA (1) CA2963720C (ja)
CY (1) CY1124033T1 (ja)
DK (1) DK3212230T3 (ja)
EA (1) EA036498B1 (ja)
ES (1) ES2864756T3 (ja)
HK (1) HK1243328A1 (ja)
HU (1) HUE054075T2 (ja)
IL (2) IL299075A (ja)
MX (1) MX2017005152A (ja)
PL (1) PL3212230T3 (ja)
PT (1) PT3212230T (ja)
SG (2) SG11201702598XA (ja)
SI (1) SI3212230T1 (ja)
WO (1) WO2016069919A1 (ja)
ZA (2) ZA201702347B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015339128C1 (en) * 2014-10-29 2021-12-16 Seagen Inc. Dosage and administration of non-fucosylated anti-CD40 antibodies
US20210001032A1 (en) * 2015-03-27 2021-01-07 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
CA3011900A1 (en) 2016-02-17 2017-08-24 Seattle Genetics, Inc. Bcma antibodies and use of same to treat cancer and immunological disorders
EP3464367B1 (en) 2016-05-27 2020-09-09 AbbVie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
BR112018074468A2 (pt) 2016-05-27 2019-03-06 Abbvie Biotherapeutics Inc. anticorpos anti-cd40 e suas utilizações
CN110546164B (zh) 2016-11-11 2023-10-20 锦湖Ht株式会社 特异性结合cd40的抗体及其用途
WO2019108733A2 (en) 2017-12-01 2019-06-06 Seattle Genetics, Inc. Cd47 antibodies and uses thereof for treating cancer
EA202092158A1 (ru) * 2018-03-13 2020-12-25 Хиберселл, Инк. Комбинированная иммунотерапия бета-глюканом и агонистом cd40
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
KR20210057053A (ko) 2018-08-23 2021-05-20 씨젠 인크. 항-tigit 항체
AU2019383548A1 (en) 2018-11-23 2021-06-24 Strike Pharma Ab Bi-specific conjugates
FR3089597B1 (fr) 2018-12-06 2020-11-20 Gaztransport Et Technigaz Cuve étanche et thermiquement isolante
KR20210104837A (ko) * 2018-12-19 2021-08-25 씨젠 인크. 항체의 제어된 푸코실화
KR20220007849A (ko) * 2019-03-18 2022-01-19 스코어 파마, 인코포레이티드 푸코실화를 억제하기 위한 화합물 및 그의 사용 방법
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US20230139944A1 (en) * 2019-06-21 2023-05-04 Board Of Regents, The University Of Texas System Targeting alpha3beta1 integrin for treatment of cancer and other diseases
US20220370418A1 (en) 2019-09-09 2022-11-24 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
TW202229348A (zh) 2020-09-30 2022-08-01 美商西健公司 使用sea-cd40治療葡萄膜黑色素瘤
EP4240415A1 (en) 2020-11-08 2023-09-13 Seagen Inc. Combination-therapy antibody drug conjugate with immune cell inhibitor
AU2021401052A1 (en) 2020-12-18 2023-06-22 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022251311A1 (en) 2021-05-25 2022-12-01 Seagen Inc. Methods of quantifying anti-cd40 antibodies
EP4363059A1 (en) 2021-06-29 2024-05-08 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2023010080A1 (en) 2021-07-30 2023-02-02 Seagen Inc. Treatment for cancer
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
WO2001024823A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
CN1450912A (zh) 2000-04-19 2003-10-22 泰诺士公司 用于治疗牛皮癣和其它炎性皮肤病的cd40拮抗剂
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US7288252B2 (en) 2000-10-02 2007-10-30 Novartis Vaccines And Diagnostics, Inc. Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies
EP2011802A3 (en) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20080199471A1 (en) 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
RU2407544C2 (ru) 2005-05-26 2010-12-27 Сиэтл Дженетикс, Инк. Гуманизированные анти-cd40-антитела и способы их применения
US20090304687A1 (en) * 2005-12-09 2009-12-10 Seattle Genetics , Inc. Methods of using cd40 binding agents
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
CA2704499C (en) 2007-11-07 2020-03-10 Genentech, Inc. Methods and compositions for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies
US8551485B2 (en) * 2008-01-23 2013-10-08 Xencor, Inc. Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cells
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013043569A1 (en) * 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
AU2015339128C1 (en) * 2014-10-29 2021-12-16 Seagen Inc. Dosage and administration of non-fucosylated anti-CD40 antibodies

Also Published As

Publication number Publication date
MX2017005152A (es) 2017-08-04
ZA201702347B (en) 2021-07-28
SI3212230T1 (sl) 2021-08-31
US11202827B2 (en) 2021-12-21
WO2016069919A1 (en) 2016-05-06
EP3212230A1 (en) 2017-09-06
IL251552B1 (en) 2023-01-01
HK1243328A1 (zh) 2018-07-13
EA201790932A1 (ru) 2017-08-31
KR20170072884A (ko) 2017-06-27
AU2015339128B2 (en) 2021-01-21
CN114522228A (zh) 2022-05-24
US11213584B2 (en) 2022-01-04
IL299075A (en) 2023-02-01
US20170137528A1 (en) 2017-05-18
BR112017008959A2 (pt) 2018-01-16
SG10201913099YA (en) 2020-02-27
IL251552B2 (en) 2023-05-01
JP2020200343A (ja) 2020-12-17
HUE054075T2 (hu) 2021-08-30
DK3212230T3 (da) 2021-04-19
JP2023126406A (ja) 2023-09-07
US20220249662A1 (en) 2022-08-11
JP6833080B2 (ja) 2021-02-24
US20240075134A1 (en) 2024-03-07
EA036498B1 (ru) 2020-11-17
US20240075135A1 (en) 2024-03-07
US20230201344A1 (en) 2023-06-29
CN107073118A (zh) 2017-08-18
EP3212230B1 (en) 2021-01-20
ES2864756T3 (es) 2021-10-14
JP7165166B2 (ja) 2022-11-02
US20220265822A1 (en) 2022-08-25
ZA202102219B (en) 2022-10-26
AU2015339128C1 (en) 2021-12-16
EP3831847A1 (en) 2021-06-09
AU2015339128A1 (en) 2017-04-20
JP2017533909A (ja) 2017-11-16
CA2963720C (en) 2024-05-14
CY1124033T1 (el) 2022-05-27
JP2021088609A (ja) 2021-06-10
JP6691113B2 (ja) 2020-04-28
IL251552A0 (en) 2017-05-29
KR20240073140A (ko) 2024-05-24
US20170333556A1 (en) 2017-11-23
CN107073118B (zh) 2022-03-01
JP2020050677A (ja) 2020-04-02
AU2021202407A1 (en) 2021-05-20
US20230201343A1 (en) 2023-06-29
PL3212230T3 (pl) 2021-07-26
CA2963720A1 (en) 2016-05-06
PT3212230T (pt) 2021-04-19
EP3212230A4 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
ZA202102219B (en) Dosage and administration of non-fucosylated anti-cd40 antibodies
HK1257056A1 (zh) 抗dll3抗體藥物綴合物以及使用方法
IL259713A (en) Anti-dr5 antibodies and methods of using them
ZA201606630B (en) Anti-ox40 antibodies and methods of use
GB201701039D0 (en) Vertically integrated continuous delivery of an application
PT3487505T (pt) Administração e dosagem de diaminofenotiazinas
PT3191167T (pt) Válvula para administração de fluidos farmacêuticos
IL246489A0 (en) Methods for using anti-steap1 antibodies and immunoconjugates
GB201419540D0 (en) Delivery of drugs
HK1223630A1 (zh) 抗- 療法的實施與用量
ZA201701492B (en) Pyrazolothiazole compound and medicine
HRP20181406T1 (hr) Farmaceutski dozni oblici
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
GB201415486D0 (en) Infusion package and method of manufature
GB201409644D0 (en) Inhalers and dosing devices for inhalers
GB201409272D0 (en) Synergistic combination of analgesic drugs